--- title: "Revvity Inc. Publishes Transcript of Fourth Quarter 2025 Earnings Call" type: "News" locale: "en" url: "https://longbridge.com/en/news/274566423.md" datetime: "2026-02-02T23:01:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274566423.md) - [en](https://longbridge.com/en/news/274566423.md) - [zh-HK](https://longbridge.com/zh-HK/news/274566423.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274566423.md) | [繁體中文](https://longbridge.com/zh-HK/news/274566423.md) # Revvity Inc. Publishes Transcript of Fourth Quarter 2025 Earnings Call Revvity Inc. has published the transcript of its Fourth Quarter 2025 Earnings Conference Call, which took place on February 2, 2026. The event featured key members of management, including the Chief Executive Officer, President and Director, the Senior Vice President & Chief Financial Officer, and the Senior Vice President of Investor Relations & Head of ESG. Analysts from Jefferies LLC and Evercore ISI also participated. During the call, management discussed the company’s strong finish to 2025, highlighting both organic growth and strategic initiatives. They emphasized the impact of their collaboration with Lilly TuneLab and the integration of functional AI capabilities, stating, “We can uniquely deliver functional AI capabilities directly to scientists in a completely transformative way.” Additionally, the acquisition of software firm ACD/Labs and a $168 million share repurchase were noted as important steps in capital deployment. The CFO commented on the company’s position, saying, “Our ability to opportunistically deploy capital like we have is a direct result of our strong free cash flow generation and conversion over the last several years since becoming Revvity, combined with our strong balance sheet, both of which I expect to continue.” Management expressed optimism about the future, driven by innovation and expected recovery in key markets. “Revvity is on a strong path with a bright future, especially as key end markets likely continue to recover over the coming months and quarters,” the CEO remarked. The full transcript can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here ### Related Stocks - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [Direxion Daily LLY Bull 2X Shares (ELIL.US)](https://longbridge.com/en/quote/ELIL.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [Revvity, Inc. (RVTY.US)](https://longbridge.com/en/quote/RVTY.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [Defiance Daily Target 2X Long LLY ETF (LLYX.US)](https://longbridge.com/en/quote/LLYX.US.md) - [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research - [Eli Lilly pushes for NHS drug price increases in return for its UK investment, FT reports](https://longbridge.com/en/news/280952509.md) - [Eli Lilly: Foundayo will be available with prescriptions accepted immediately and shipping from April 6](https://longbridge.com/en/news/281395595.md) - [Nikulski Financial Inc. Raises Stock Holdings in Eli Lilly and Company $LLY](https://longbridge.com/en/news/281624218.md) - [InSilico Medicine Strikes Multi-Billion-Dollar AI Drug Discovery Deal With Eli Lilly](https://longbridge.com/en/news/280909399.md) - [Eli Lilly: Eligible Medicare Part D Individuals May Get Foundayo for $50/Month, from as Soon as July 1, 2026](https://longbridge.com/en/news/281395586.md)